Cathie Wood’s highest conviction stock picks for 2024 include one with ‘life-changing innovation’
The innovation investor said her biotech darling CRISPR Therapeutics in the multiomics space has the potential to be her top
Read More
CRISPR Therapeutics AG
U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease
Casgevy uses the Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans.
Read More
Cathie Wood’s Innovation ETF is up 31% in November, notching its best month ever
The fund rebounded drastically from three straight months of losses, pushing 2023 gains to 47%. Source link
Read More